Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Therapy in Advanced Salivary Gland Carcinoma Based on Molecular Typing
NCT05924256Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, rezvilutamide, tizetatug rezetecan in salivary gland carcinoma (SGC), sponsored by Fudan University. Started Jul 2023; status: active, not recruiting.
02
Drugs
trastuzumab rezetecanrezvilutamidetizetatug rezetecan
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT05924256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05924256.